Key Highlights
● Shares closed at $140.66 at their last session, up 0.57% on the day.
● Leidos reported record second-quarter 2026 Revenue of about $4.56 billion, up 7% year over year, and raised its full-year 2026 guidance.
● The company reported a robust defense book-to-bill ratio of about 2.2, indicating strong new-business momentum.
● Its health segment faced headwinds even as defense and national-security Demand remained strong.
Leidos Holdings (NYSE:LDOS) shares closed at $140.66 at their last session, up 0.57% on the day, as the provider of technology and services to defense, intelligence, civil and health customers continues to benefit from robust national-security demand. For investors, the question is whether the rally can build as the company capitalizes on national-security and technology spending.
Leidos provides services and solutions across national security, defense, intelligence, civil government and health, including IT modernization, systems integration, and increasingly AI and digital capabilities.
Latest Developments
In its second-quarter 2026 results, Leidos reported record revenue of about $4.56 billion, up 7% year over year, and raised its full-year 2026 guidance, with its shares having jumped on the strong results. The company reported a robust defense book-to-bill ratio of about 2.2, indicating strong new-business momentum in its national-security business, while noting headwinds in its health segment.
Management emphasized the strength of its defense and national-security demand, its backlog, and its focus on higher-value technology and digital solutions, framing the quarter as evidence of accelerating momentum.
Financial and Business Position
Leidos' record revenue, raised guidance and strong defense book-to-bill reflect robust demand in national security and defense, where the company's scale, capabilities and Backlog provide durable advantages, supporting future revenue growth. Its Diversification across defense, intelligence, civil and health provides balance, though its health segment faced headwinds.
Stock-Market Context
Shares closed at $140.66 at their last session, up 0.57% on the day. The stock carries a favorable analyst rating in the data underlying this article, and the warming sentiment reflects the record revenue and raised guidance. The rally-building case rests on continued strong defense demand and bookings, backlog conversion, and its higher-value solutions. The cautionary case is the dependence on government spending, the headwinds in its health business, and the execution risk of large programs.
A Leading Indicator Pointing Higher
Leidos delivered a quarter that reinforced its position as a prime beneficiary of robust national-security and defense spending, and the standout metric was its defense book-to-bill ratio of roughly 2.2, which is a powerful leading indicator. A book-to-bill above one means a company is booking new business faster than it is burning through its backlog, and a ratio as high as 2.2 signals exceptionally strong demand and a rapidly growing pipeline of future revenue.
Combined with record revenue and a raised full-year outlook, the quarter demonstrated that Leidos is capturing the elevated demand for defense, intelligence and technology modernization. Its scale, its entrenched relationships across defense, intelligence and civil agencies, and its shift toward higher-value digital and AI-enabled solutions are durable advantages, while its diversification provides balance, though its health segment faced headwinds worth monitoring.
Investors watching this story will want to see revenue growth, the book-to-bill ratio and bookings, especially in defense, and the performance of its health segment. For investors, whether the rally can build depends on the strong defense demand and bookings continuing to translate into revenue growth while the health-segment headwinds ease, sustaining the momentum that the exceptional book-to-bill and raised guidance signaled.






Please wait processing your request...